The US-based Veeda Oncology  has acquired International Oncology Network (ION) Clinical Research. This acquisition would provide Veeda with immediate access to the 50 ION sites that conduct oncology clinical research in the US.

Veeda Oncology is a global oncology CRO with operations in India, Eastern Europe, Western Europe and US. The company is a full service oncology CRO for phase I through phase IV studies with the unique capability of providing rapid and strong global patient accrual with an effective cost structure. The companies also disclosed that they have entered into a 5 year exclusive agreement under which Veeda Oncology would provide clinical research support to the ION Network of sites.
Referring to the acquisition, Binoy Gardi, co-group managing director and co-founder, Veeda Group, said, "The agreement with ION substantially increases our ability to provide our sponsors with rapid global accrual of oncology patients beyond our relationships with institutions in India, Eastern Europe, Western Europe as well as our current site relationships in US."
"The access to the 50 ION clinical research sites significantly compliments our strategy of rapid access to oncology patients for global clinical trials. In addition, all of the personnel of ION Clinical Research will be joining Veeda Oncology and we are very pleased to add such terrific oncology professionals," noted Matt Bowman, president and CEO, Veeda Oncology.
Veeda Oncology is part of the Veeda Group that includes Veeda Clinical Research (Veeda CR), which is a full service global CRO specialising in early clinical development of drugs with top class clinical pharmacology units in UK, Europe and India.